HYR-PB21 offers effective analgesia and lowers need for opioids after hemorrhoidectomy

A randomized controlled trial showed that local infiltration of a single dose of HYR-PB21 was more effective than a single dose of Bupivacaine HCl to treat postsurgical pain in people undergoing hemorrhoidectomy. Jinjie Cui et al. set out to explore the analgesic effectiveness and safety profile of a sustained-release formulation of Bupivacaine in people who had undergone hemorrhoidectomy.

After prolapsing hemorrhoids surgery, subjects were randomized to receive a single dose of either 75 mg Bupivacaine HCl or 150 mg/300 mg HYR-PB21. In order to create a cumulative pain score, postoperative pain was evaluated with the aid of numeric rating scale (NRS) at rest. Both the overall amount of rescue opioid used and the percentage of participants who received rescue opioids were evaluated.

A total of 71 out of 72 individuals with hemorrhoidectomy completed the research. In an intention-to-treat analysis, the average cumulative pain score through 72 hours following surgery was reduced in the 300 mg HYR-PB21 group (87 scores), compared to the Bupivacaine HCl group (166 scores). With Bupivacaine HCl as the control group, there was a dose-response impact in lowering overall opioid consumption and the percentage of rescue opioid use between the 150 mg and 300 mg HYR-PB21 groups.

The HYR-PB21 group did not demonstrate more negative effects when compared to the Bupivacaine HCl group. In comparison to a single dose of Bupivacaine HCl, local infiltration of a single dosage of HYR-PB21 demonstrated superior effectiveness in the management of postoperative pain with comparable side effects.